Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00942162 · ClinicalTrials.gov registry record · Phase 2
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT00942162 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 125 participants.
The verdict
NCT00942162, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the clinical activity of the GSK2132231A immunotherapeutic in patients with MAGE-A3 positive unresectable metastatic melanoma presenting with the predictive gene signature.
Interventions
- BIOLOGICAL Immunotherapeutic GSK2132231A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2009-08-14 |
| Est. Completion | 2015-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00942162
The ClinicalTrials.gov registry entry for NCT00942162 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Immunotherapeutic GSK2132231A is the first listed.
NCT00942162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00942162 about?
NCT00942162 is a clinical study titled "A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma". The objective of this study is to evaluate the clinical activity of the GSK2132231A immunotherapeutic in patients with MAGE-A3 positive unresectable metastatic melanoma presenting with the predictive gene signature.
What is the current status of trial NCT00942162?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2009-08-14. Estimated completion is 2015-04-01.
What interventions are being tested in trial NCT00942162?
The interventions under investigation include: Immunotherapeutic GSK2132231A (BIOLOGICAL).
Who is sponsoring clinical trial NCT00942162?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.